Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$432.00
0.050.01%
At close: -
$432.00
0.000.00%
After Hours: Mar 28, 4:34 PM EDT
Comments
Loading...
Elevance Health Analyst Ratings and Price Targets | NYSE:ELV | Benzinga
Elevance Health Inc has a consensus price target of $542.19 based on the ratings of 25 analysts. The high is $649 issued by Baird on May 30, 2024. The low is $405.4 issued by Argus Research on January 29, 2025. The 3 most-recent analyst ratings were released by Argus Research, Wells Fargo, and Cantor Fitzgerald on January 29, 2025, January 28, 2025, and January 24, 2025, respectively. With an average price target of $456.13 between Argus Research, Wells Fargo, and Cantor Fitzgerald, there's an implied 5.59% upside for Elevance Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Argus Research
Wells Fargo
Cantor Fitzgerald
Barclays
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Elevance Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/29/2025 | Buy Now | -6.16% | Argus Research | David Toung71% | $405.4 → $405.4 | Reiterates | Hold → Hold | Get Alert |
| 01/28/2025 | Buy Now | 10.65% | Wells Fargo | Stephen Baxter55% | $483 → $478 | Maintains | Overweight | Get Alert |
| 01/24/2025 | Buy Now | 12.27% | Cantor Fitzgerald | Sarah James51% | $485 → $485 | Reiterates | Overweight → Overweight | Get Alert |
| 01/24/2025 | Buy Now | 18.52% | Barclays | Andrew Mok55% | $501 → $512 | Maintains | Overweight | Get Alert |
| 01/06/2025 | Buy Now | 11.11% | Truist Securities | David Macdonald67% | $520 → $480 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 16.9% | Mizuho | Ann Hynes86% | $585 → $505 | Maintains | Outperform | Get Alert |
| 11/04/2024 | Buy Now | 14.58% | Wells Fargo | Stephen Baxter55% | $593 → $495 | Maintains | Overweight | Get Alert |
| 10/23/2024 | Buy Now | 27.55% | Morgan Stanley | Erin Wright75% | $643 → $551 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 15.97% | Barclays | Andrew Mok55% | $622 → $501 | Maintains | Overweight | Get Alert |
| 10/21/2024 | Buy Now | 12.04% | TD Cowen | Ryan Langston27% | $589 → $484 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | — | Argus Research | — | — | Downgrade | Buy → Hold | Get Alert |
| 10/18/2024 | Buy Now | 28.47% | UBS | A.J. Rice68% | $605 → $555 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 20.37% | Truist Securities | David Macdonald67% | $620 → $520 | Reiterates | Buy → Buy | Get Alert |
| 10/18/2024 | Buy Now | 10.65% | RBC Capital | Ben Hendrix60% | $585 → $478 | Maintains | Outperform | Get Alert |
| 10/18/2024 | Buy Now | 12.27% | Cantor Fitzgerald | Sarah James51% | $600 → $485 | Maintains | Overweight | Get Alert |
| 10/10/2024 | Buy Now | 43.98% | Barclays | Andrew Mok55% | $611 → $622 | Maintains | Overweight | Get Alert |
| 10/01/2024 | Buy Now | 38.89% | Cantor Fitzgerald | Sarah James51% | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 38.89% | Cantor Fitzgerald | Sarah James51% | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 09/10/2024 | Buy Now | 38.89% | Cantor Fitzgerald | Sarah James51% | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 42.36% | Stephens & Co. | Scott Fidel68% | $615 → $615 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 38.89% | Cantor Fitzgerald | Sarah James51% | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 07/23/2024 | Buy Now | 38.89% | Cantor Fitzgerald | Sarah James51% | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 07/22/2024 | Buy Now | 37.27% | Wells Fargo | Stephen Baxter55% | $600 → $593 | Maintains | Overweight | Get Alert |
| 07/19/2024 | Buy Now | 36.34% | TD Cowen | Ryan Langston27% | $624 → $589 | Maintains | Buy | Get Alert |
| 07/18/2024 | Buy Now | 41.44% | Barclays | Andrew Mok55% | $621 → $611 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 35.42% | RBC Capital | Ben Hendrix60% | $575 → $585 | Maintains | Outperform | Get Alert |
| 07/18/2024 | Buy Now | 22.69% | B of A Securities | Kevin Fischbeck67% | $646 → $530 | Downgrade | Buy → Neutral | Get Alert |
| 07/15/2024 | Buy Now | 43.52% | Truist Securities | David Macdonald67% | $600 → $620 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 38.89% | Cantor Fitzgerald | Sarah James51% | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 48.84% | Morgan Stanley | Erin Wright75% | → $643 | Initiates | → Overweight | Get Alert |
| 06/12/2024 | Buy Now | 38.89% | Cantor Fitzgerald | Sarah James51% | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 06/11/2024 | Buy Now | 42.36% | Stephens & Co. | Scott Fidel68% | $615 → $615 | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2024 | Buy Now | 49.54% | B of A Securities | Kevin Fischbeck67% | $621 → $646 | Maintains | Buy | Get Alert |
| 05/30/2024 | Buy Now | 46.06% | JP Morgan | Lisa Gill59% | $628 → $631 | Maintains | Overweight | Get Alert |
| 05/30/2024 | Buy Now | 50.23% | Baird | Michael Ha49% | → $649 | Initiates | → Outperform | Get Alert |
| 04/24/2024 | Buy Now | 35.42% | Mizuho | Ann Hynes86% | $575 → $585 | Maintains | Buy | Get Alert |
| 04/19/2024 | Buy Now | 33.1% | RBC Capital | Ben Hendrix60% | $574 → $575 | Maintains | Outperform | Get Alert |
| 04/19/2024 | Buy Now | 40.05% | UBS | A.J. Rice68% | $585 → $605 | Maintains | Buy | Get Alert |
| 04/19/2024 | Buy Now | 38.89% | Wells Fargo | Stephen Baxter55% | $557 → $600 | Maintains | Overweight | Get Alert |
| 04/19/2024 | Buy Now | 38.89% | Truist Securities | David Macdonald67% | $580 → $600 | Reiterates | Buy → Buy | Get Alert |
| 04/19/2024 | Buy Now | 39.81% | Jefferies | David Windley74% | $602 → $604 | Maintains | Buy | Get Alert |
| 04/19/2024 | Buy Now | 43.75% | Barclays | Andrew Mok55% | $584 → $621 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | 34.26% | Cantor Fitzgerald | Sarah James51% | $580 → $580 | Reiterates | Overweight → Overweight | Get Alert |
| 04/08/2024 | Buy Now | 28.94% | Wells Fargo | Stephen Baxter55% | $561 → $557 | Maintains | Overweight | Get Alert |
| 04/04/2024 | Buy Now | 34.26% | Cantor Fitzgerald | Sarah James51% | $580 → $580 | Reiterates | Overweight → Overweight | Get Alert |
| 03/06/2024 | Buy Now | 35.19% | Barclays | Andrew Mok55% | → $584 | Initiates | → Overweight | Get Alert |
| 02/14/2024 | Buy Now | 34.26% | Cantor Fitzgerald | Sarah James51% | $547 → $580 | Maintains | Overweight | Get Alert |
| 02/02/2024 | Buy Now | 26.62% | Cantor Fitzgerald | Sarah James51% | $547 → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 01/25/2024 | Buy Now | 26.62% | Cantor Fitzgerald | Sarah James51% | $547 → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 01/25/2024 | Buy Now | 32.87% | RBC Capital | Ben Hendrix60% | $572 → $574 | Maintains | Outperform | Get Alert |
| 01/19/2024 | Buy Now | 26.62% | Cantor Fitzgerald | Sarah James51% | $547 → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 11/21/2023 | Buy Now | 26.62% | Cantor Fitzgerald | Sarah James51% | → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 11/17/2023 | Buy Now | 27.78% | JP Morgan | Lisa Gill59% | $569 → $552 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | 26.62% | Cantor Fitzgerald | Sarah James51% | → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 10/19/2023 | Buy Now | 35.88% | Morgan Stanley | Michael Ha49% | $585 → $587 | Maintains | Overweight | Get Alert |
| 09/14/2023 | Buy Now | 26.62% | Cantor Fitzgerald | Sarah James51% | → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2023 | Buy Now | 35.42% | Morgan Stanley | Michael Ha49% | $571 → $585 | Maintains | Overweight | Get Alert |
| 07/24/2023 | Buy Now | 35.42% | TD Cowen | Gary Taylor59% | $564 → $585 | Maintains | Outperform | Get Alert |
| 07/20/2023 | Buy Now | 32.41% | RBC Capital | Ben Hendrix60% | → $572 | Reiterates | Outperform → Outperform | Get Alert |
| 07/20/2023 | Buy Now | 28.47% | Stephens & Co. | Scott Fidel68% | → $555 | Reiterates | Overweight → Overweight | Get Alert |
| 07/13/2023 | Buy Now | 33.1% | UBS | Kevin Caliendo71% | $610 → $575 | Maintains | Buy | Get Alert |
| 07/12/2023 | Buy Now | — | Wolfe Research | Justin Lake33% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 07/07/2023 | Buy Now | 23.84% | JP Morgan | Lisa Gill59% | $572 → $535 | Maintains | Overweight | Get Alert |
| 06/20/2023 | Buy Now | 29.63% | Truist Securities | Tobey Sommer69% | $580 → $560 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | 32.18% | Morgan Stanley | Michael Ha49% | $500 → $571 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/24/2023 | Buy Now | 29.86% | Wells Fargo | Stephen Baxter55% | $597 → $561 | Maintains | Overweight | Get Alert |
| 04/21/2023 | Buy Now | 27.31% | Loop Capital | Joseph France65% | $565 → $550 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 26.62% | Cantor Fitzgerald | Sarah James51% | → $547 | Initiates | → Overweight | Get Alert |
| 04/20/2023 | Buy Now | 30.56% | TD Cowen | Gary Taylor59% | $577 → $564 | Maintains | Outperform | Get Alert |
| 03/28/2023 | Buy Now | 32.41% | RBC Capital | Ben Hendrix60% | $523 → $572 | Upgrade | Sector Perform → Outperform | Get Alert |
| 03/24/2023 | Buy Now | 34.26% | Truist Securities | Tobey Sommer69% | $610 → $580 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | -83.56% | Wells Fargo | Stephen Baxter55% | $79 → $71 | Maintains | Equal-Weight | Get Alert |
| 03/08/2023 | Buy Now | 32.18% | Deutsche Bank | George Hill62% | $581 → $571 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | 32.41% | JP Morgan | Lisa Gill59% | $555 → $572 | Maintains | Overweight | Get Alert |
| 01/26/2023 | Buy Now | 21.06% | RBC Capital | Ben Hendrix60% | $505 → $523 | Maintains | Sector Perform | Get Alert |
| 01/26/2023 | Buy Now | 34.26% | SVB Leerink | Whit Mayo67% | → $580 | Reiterates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | 40.97% | Wells Fargo | Stephen Baxter55% | $557 → $609 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | 33.1% | Mizuho | Ann Hynes86% | $545 → $575 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 34.49% | Deutsche Bank | George Hill62% | $576 → $581 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 15.74% | Morgan Stanley | Ricky Goldwasser78% | $485 → $500 | Maintains | Equal-Weight | Get Alert |
| 09/09/2022 | Buy Now | 33.1% | B of A Securities | Kevin Fischbeck67% | $535 → $575 | Upgrade | Neutral → Buy | Get Alert |
| 08/22/2022 | Buy Now | 34.26% | SVB Leerink | Whit Mayo67% | $490 → $580 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/28/2022 | Buy Now | 28.94% | Wells Fargo | Stephen Baxter55% | $580 → $557 | Maintains | Overweight | Get Alert |
| 07/25/2022 | Buy Now | 12.27% | Morgan Stanley | Ricky Goldwasser78% | $533 → $485 | Maintains | Equal-Weight | Get Alert |
| 07/22/2022 | Buy Now | 13.43% | SVB Leerink | Whit Mayo67% | $555 → $490 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Elevance Health (ELV) stock?
The latest price target for Elevance Health (NYSE:ELV) was reported by Argus Research on January 29, 2025. The analyst firm set a price target for $405.40 expecting ELV to fall to within 12 months (a possible -6.16% downside). 45 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elevance Health (ELV)?
The latest analyst rating for Elevance Health (NYSE:ELV) was provided by Argus Research, and Elevance Health reiterated their hold rating.
When was the last upgrade for Elevance Health (ELV)?
The last upgrade for Elevance Health Inc happened on April 27, 2023 when Morgan Stanley raised their price target to $571. Morgan Stanley previously had an equal-weight for Elevance Health Inc.
When was the last downgrade for Elevance Health (ELV)?
The last downgrade for Elevance Health Inc happened on October 18, 2024 when Argus Research changed their price target from N/A to N/A for Elevance Health Inc.
When is the next analyst rating going to be posted or updated for Elevance Health (ELV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevance Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevance Health was filed on January 29, 2025 so you should expect the next rating to be made available sometime around January 29, 2026.
Is the Analyst Rating Elevance Health (ELV) correct?
While ratings are subjective and will change, the latest Elevance Health (ELV) rating was a reiterated with a price target of $405.40 to $405.40. The current price Elevance Health (ELV) is trading at is $432.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.